journal article·2022-08Open access

Silk fibers assisted long-term 3D culture of human primary urinary stem cells via inhibition of senescence-associated genes: Potential use in the assessment of chronic mitochondrial toxicity

Huifen Ding, Sunil George, Xiaoyan Iris Leng, Michael Ihnat, Jian-Xing Ma, Guochun Jiang, David Margolis, Julie Dumond, Yuanyuan Zhang

Abstract

Despite being widely applied in drug development, existing in vitro 2D cell-based models are not suitable to assess chronic mitochondrial toxicity. A novel in vitro assay system mimicking in vivo micro-environment for this purpose is urgently needed. The goal of this study is to establish a 3D cell platform as a reliable, sensitive, cost-efficient, and high-throughput assay to predict drug-induced mitochondrial toxicity. We evaluated a long-term culture of human primary urine-derived stem cells (USC) seeded in 3D silk fiber matrix (3D USC-SFM) and further tested chronic mitochondrial toxicity induced by Zalcitabine (ddC, a nucleoside reverse transcriptase inhibitor) as a test drug, compared to USC grown in spheroids. The numbers of USC remain steady in 3D spheroids for 4 weeks and 3D SFM for 6 weeks. However, the majority (95%) of USC survived in 3D SFM, while cell numbers significantly declined in 3D spheroids at 6 weeks. Highly porous SFM provides large-scale numbers of cells by increasing the yield of USC 125-fold/well, which enables the carrying of sufficient cells for multiple experiments with less labor and lower cost, compared to 3D spheroids. The levels of mtDNA content and mitochondrial superoxide dismutase2 [SOD2] as an oxidative stress biomarker and cell senescence genes (RB and P16, p21) of USC were all stably retained in 3D USC-SFM, while those were significantly increased in spheroids. mtDNA content and mitochondrial mass in both 3D culture models significantly decreased six weeks after treatment of ddC (0.2, 2, and 10 μM), compared to 0.1% DMSO control. Levels of complexes I, II, and III significantly decreased in 3D SFM-USC treated with ddC, compared to only complex I level which declined in spheroids. A dose- and time-dependent chronic MtT displayed in the 3D USC-SFM model, but not in spheroids. Thus, a long-term 3D culture model of human primary USC provides a cost-effective and sensitive approach potential for the assessment of drug-induced chronic mitochondrial toxicity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Silk-based biomaterials and applications · Mesenchymal stem cell research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. 3D spheroids of human primary urine-derived stem cells in the assessment of drug-induced mitochondrial toxicity10.3390/pharmaceutics14051042 ↗
2. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway10.1097/00002030-199814000-00004 ↗
3. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity10.1016/S0149-2918(00)80064-8 ↗
4. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?10.1093/jac/dkp316 ↗
5. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy10.1177/135965350601100108 ↗
6. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?10.1097/01.aids.0000131386.38103.37 ↗
7. Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury10.1097/QAD.0000000000001466 ↗
8. International Maternal Pediatric Adolescent ACTCST: the impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-110.1097/QAD.0b013e3283578bfa ↗
9. Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs10.1021/acs.chemrestox.8b00246 ↗
10. Physiologically relevant concentrations of dolutegravir, emtricitabine, and efavirenz induce distinct metabolic alterations in HeLa epithelial and BV2 microglial cells10.3389/fimmu.2021.639378 ↗
11. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy10.1016/0140-6736(91)91294-5 ↗
12. Mitochondrial myopathy caused by long-term zidovudine therapy10.1056/NEJM199004193221602 ↗
13. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes10.1093/cid/ciaa259 ↗
14. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors10.1089/adt.2014.573 ↗
15. High drug attrition rates--where are we going wrong?10.1038/nrclinonc.2011.34 ↗
16. The limited IN vitro lifetime OF human diploid cell strains10.1016/0014-4827(65)90211-9 ↗
17. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs10.1002/bit.26845 ↗
18. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease10.1038/srep25187 ↗
19. Long-term maintenance of functional primary human hepatocytes in 3D gelatin matrices produced by solution blow spinning10.1038/s41598-021-99659-1 ↗
20. 3-D human renal tubular organoids generated from urine-derived stem cells for nephrotoxicity screening10.1021/acsbiomaterials.0c01468 ↗
21. Design and manufacture of 3D cell culture plate for mass production of cell-spheroids10.1038/s41598-019-50186-0 ↗
22. Tissue-engineered conduit using urine-derived stem cells seeded bacterial cellulose polymer in urinary reconstruction and diversion10.1016/j.biomaterials.2010.07.108 ↗
23. Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering10.1089/ten.tea.2009.0625 ↗
24. Human urine-derived stem cells seeded in a modified 3D porous small intestinal submucosa scaffold for urethral tissue engineering10.1016/j.biomaterials.2010.10.006 ↗
25. Urethral reconstruction with autologous urine-derived stem cells seeded in three-dimensional porous small intestinal submucosa in a rabbit model10.1186/s13287-017-0500-y ↗
26. The importance of three-dimensional scaffold structure on stemness maintenance of mouse embryonic stem cells10.1016/j.biomaterials.2014.05.060 ↗
27. Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering10.1016/j.biomaterials.2009.10.001 ↗
28. Optimization of a natural collagen scaffold to aid cell-matrix penetration for urologic tissue engineering10.1016/j.biomaterials.2009.04.008 ↗
29. Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering10.1016/j.biomaterials.2009.10.001 ↗
30. Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction10.1186/s13287-018-1035-6 ↗
31. Three-dimensional culture of hepatocytes on porcine liver tissue-derived extracellular matrix10.1016/j.biomaterials.2011.06.005 ↗
32. Recombinant spider silk-silica hybrid scaffolds with drug-releasing properties for tissue engineering applications10.1002/marc.201900426 ↗
33. Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen10.1016/j.biomaterials.2004.04.012 ↗
34. Three-dimensional collagen matrix induces a mechanosensitive invasive epithelial phenotype10.1038/srep42088 ↗
35. Stress relaxing hyaluronic acid-collagen hydrogels promote cell spreading, fiber remodeling, and focal adhesion formation in 3D cell culture10.1016/j.biomaterials.2017.11.004 ↗
36. Gelatin-polysaccharide composite scaffolds for 3D cell culture and tissue engineering: towards natural therapeutics10.1002/btm2.10124 ↗
37. Electrospun PGA/gelatin nanofibrous scaffolds and their potential application in vascular tissue engineering10.2147/IJN.S24312 ↗
38. Preparation of 3D fibrin scaffolds for stem cell culture applications10.3791/3641 ↗
39. 3D cell culture in alginate hydrogels10.3390/microarrays4020133 ↗
40. 3D PLGA scaffolds improve differentiation and function of bone marrow mesenchymal stem cell-derived hepatocytes10.1089/scd.2009.0415 ↗
41. The use of flow perfusion culture and subcutaneous implantation with fibroblast-seeded PLLA-collagen 3D scaffolds for abdominal wall repair10.1016/j.biomaterials.2010.02.010 ↗
42. Porous nanofibrous PLLA scaffolds for vascular tissue engineering10.1016/j.biomaterials.2010.07.028 ↗
43. Partially nanofibrous architecture of 3D tissue engineering scaffolds10.1016/j.biomaterials.2009.08.012 ↗
44. The biomedical use of silk: past, present, future10.1002/adhm.201800465 ↗
45. The use of bi-layer silk fibroin scaffolds and small intestinal submucosa matrices to support bladder tissue regeneration in a rat model of spinal cord injury10.1016/j.biomaterials.2014.05.044 ↗
46. Silk fibroin scaffolds for urologic tissue engineering10.1007/s11934-015-0567-x ↗
47. State-of-Art functional biomaterials for tissue engineering10.3389/fmats.2019.00172 ↗
48. Silk-based biomaterials for cardiac tissue engineering10.1002/adhm.202000735 ↗
49. Establishment of 3D culture and induction of osteogenic differentiation of pre-osteoblasts using wet-collected aligned scaffolds10.1016/j.msec.2016.10.002 ↗
50. Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size10.1089/ten.teb.2012.0437 ↗
51. Drug-induced mitochondrial dysfunction and cardiotoxicity10.1152/ajpheart.00554.2015 ↗
52. The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity10.1016/j.tiv.2018.08.001 ↗
53. Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs10.1021/acs.chemrestox.8b00246 ↗
54. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC)10.1038/labinvest.3780367 ↗
55. Urine derived cells are a potential source for urological tissue reconstruction
56. Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology10.1002/stem.1424 ↗
57. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering10.1089/ten.tea.2010.0637 ↗
58. Urine-derived stem cells: a novel and versatile progenitor source for cell-based therapy and regenerative medicine10.1016/j.gendis.2014.07.001 ↗
59. Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells10.1016/j.mce.2016.03.001 ↗
60. Guo · 2020
61. Intratunical injection of human urine-derived stem cells derived exosomes prevents fibrosis and improves erectile function in a rat model of Peyronie's disease10.1111/and.13831 ↗
62. Immunomodulatory effect of urine-derived stem cells on inflammatory bowel diseases via downregulating Th1/Th17 immune responses in a PGE2-dependent manner10.1093/ecco-jcc/jjz200 ↗
63. A cocktail of growth factors released from a heparin hyaluronic-acid hydrogel promotes the myogenic potential of human urine-derived stem cells in vivo10.1016/j.actbio.2020.02.005 ↗
64. Transplantation of human urine-derived stem cells transfected with pigment epithelium-derived factor to protect erectile function in a rat model of cavernous nerve injury10.3727/096368916X691448 ↗
65. Urine-derived stem cells for the therapy of diabetic nephropathy mouse model
66. Therapeutic effects of human urine-derived stem cells in a rat model of cisplatin-induced acute kidney injury in vivo and in vitro
67. Extracellular vesicles secreted by human urine-derived stem cells promote ischemia repair in a mouse model of hind-limb ischemia10.1159/000490214 ↗
68. Urine-derived stem cells for urological injection therapy
69. Bioglass enhanced wound healing ability of urine-derived stem cells through promoting paracrine effects between stem cells and recipient cells
70. Urine-derived stem cells for potential use in treatment of urethral sphincter dysfunction
71. Reno-protection of urine-derived stem cells in A chronic kidney disease rat model induced by renal ischemia and nephrotoxicity10.7150/ijbs.37550 ↗
72. Characterization of rabbit urine-derived stem cells for potential application in lower urinary tract tissue regeneration10.1007/s00441-018-2885-z ↗
73. 181 cell therapy with autologous urine-derived stem cells for vesicoureteral reflux
74. Human urine-derived stem cells originate from parietal stem cells
75. Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction10.1186/s13287-018-1035-6 ↗
76. Human urine-derived stem cells or their secretome alone facilitate functional recovery in a rat model of stress urinary incontinence
77. Paracrine effects of human urine-derived stem cells in treatment of female stress urinary incontinence in a rodent model
78. Silver nanoparticles promote osteogenic differentiation of human urine-derived stem cells at noncytotoxic concentrations10.2147/IJN.S59753 ↗
79. Urine-derived stem cells for potential use in bladder repair10.1186/scrt458 ↗
80. Human urine-derived stem cells alone or genetically-modified with FGF2 Improve type 2 diabetic erectile dysfunction in a rat model10.1371/journal.pone.0092825 ↗
81. Human urine-derived stem cells lessen inflammation and fibrosis within kidney tissue in a rodent model of aging-related renal insufficiency
82. Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors10.1016/j.biomaterials.2012.10.038 ↗
83. Exosomes from human urine-derived stem cells enhanced neurogenesis via miR-26a/HDAC6 axis after ischaemic stroke10.1111/jcmm.14774 ↗
84. Therapeutic effect of urine-derived stem cells for protamine/lipopolysaccharide-induced interstitial cystitis in a rat model10.1186/s13287-017-0547-9 ↗
85. Self-renewal and differentiation capacity of urine-derived stem cells after urine preservation for 24 hours10.1371/journal.pone.0053980 ↗
86. Human urine-derived stem cells can be induced into osteogenic lineage by silicate bioceramics via activation of the Wnt/beta-catenin signaling pathway10.1016/j.biomaterials.2015.03.029 ↗
87. Human urine-derived stem cells in combination with polycaprolactone/gelatin nanofibrous membranes enhance wound healing by promoting angiogenesis10.1186/s12967-014-0274-2 ↗
88. Human urine-derived stem cell differentiation to endothelial cells with barrier function and nitric oxide production10.1002/sctm.18-0040 ↗
89. Preparation and metabolic assay of 3-dimensional spheroid Co-cultures of pancreatic cancer cells and fibroblasts
90. Metabolic Profiling of healthy and cancerous tissues in 2D and 3D10.1038/s41598-017-15325-5 ↗
91. Multiparametric assessment of mitochondrial respiratory inhibition in HepG2 and RPTEC/TERT1 cells using a panel of mitochondrial targeting agrochemicals10.1007/s00204-020-02792-5 ↗
92. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA410.1126/science.aaa5612 ↗
93. PCR based determination of mitochondrial DNA copy number in multiple species10.1007/978-1-4939-1875-1_3 ↗
94. Mitochondrial biogenesis and clearance: a balancing act10.1111/febs.13820 ↗
95. Mechanotransduction in the renal tubule10.1152/ajprenal.00453.2010 ↗
96. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy10.1128/mBio.01741-15 ↗
97. The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine10.1016/j.taap.2020.115163 ↗
98. In vitro toxicity model: upgrades to bridge the gap between preclinical and clinical research
99. Drug-induced nephrotoxicity assessment in 3D cellular models10.3390/mi13010003 ↗
100. Drug-induced mitochondrial toxicity in the geriatric population: challenges and future directions10.3390/biology8020032 ↗